Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
MedX Health Corp (MDXHF)
Mississauga, ON, CA
MedX Health Corp is a medical technology company specializing in both diagnostic tools and therapeutic devices. The firm develops, manufactures, and markets advanced solutions for skin screening and light-based therapy, serving customers across Canada, the United States, and international markets. Its diagnostic portfolio includes SIAscopy, a cutting-edge medical device technology designed to scan skin for early detection of suspicious moles and lesions. MedX also offers a suite of imaging systems – SIAMETRICS, SIMSYS, and MoleMate – which provide real-time visuals, allowing physicians and dermatologists to rapidly assess various types of moles and lesions. On the therapeutic side, MedX produces phototherapeutic medical devices. These devices employ low-level laser and LED light energy to address pain relief and promote tissue repair, primarily within the rehabilitation sector. To enhance accessibility, MedX operates the DermSecure telemedicine platform. This web-based system enables the remote operation of its SIAscopy technology, facilitating the deployment of its diagnostic tools in a network of third-party locations. Through DermSecure, patient images of moles and lesions, alongside other relevant clinical data, can be securely transmitted to specialist physicians for expert remote assessment. The company was founded in 1999 and its headquarters are situated in Mississauga, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +340.00% | +300.00% | +5,400.00% | -26.67% | -63.33% | -12.00% | -82.40% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%-3.4% Q1'26: +60.4% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-54.0% Q1'26: +35.6% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%-1,189.8% Q1'26: -452.8% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%-906.9% Q1'26: -514.8% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%— Q1'26: +178.8% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+11.1% Q1'26: +20.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-1.88× Q1'26: -2.06× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
530.1K
est: 501.1K (+5.8%)
|
563.1K
est: 500.2K (+12.6%)
|
510.6K
est: 10.09M (-94.9%)
|
456.1K
est: 18.09M (-97.5%)
|
489.7K
est: 19.63M (-97.5%)
|
472.9K
est: 499.6K (-5.3%)
|
3.48M
3.48M – 3.48M
+596.9% YoY
|
11.24M
11.24M – 11.24M
+222.9% YoY
|
18.73M
18.73M – 18.73M
+66.6% YoY
|
| EBITDA |
-3.10M
est: -501.1K (-518.6%)
|
-4.54M
est: -500.2K (-807.8%)
|
-3.82M
est: -10.09M (+62.2%)
|
-2.38M
est: -18.09M (+86.9%)
|
-2.26M
est: -19.63M (+88.5%)
|
-4.24M
est: -499.6K (-748.1%)
|
-3.48M
-3.48M – -3.48M
-596.9% YoY
|
-11.24M
-11.24M – -11.24M
-222.9% YoY
|
-18.73M
-18.73M – -18.73M
-66.6% YoY
|
| EBIT |
-3.14M
est: -501.1K (-526.8%)
|
-4.59M
est: -500.2K (-818.2%)
|
-3.86M
est: -10.09M (+61.7%)
|
-2.43M
est: -18.09M (+86.6%)
|
-2.30M
est: -19.63M (+88.3%)
|
-4.29M
est: -499.6K (-758.4%)
|
-3.48M
-3.48M – -3.48M
-596.9% YoY
|
-11.24M
-11.24M – -11.24M
-222.9% YoY
|
-18.73M
-18.73M – -18.73M
-66.6% YoY
|
| Net Income |
-3.20M
est: -2.67M (-19.7%)
|
-5.32M
est: -2.67M (-99.5%)
|
-5.13M
est: 2.83M (-281.2%)
|
-4.58M
est: 7.82M (-158.5%)
|
-3.65M
est: 9.43M (-138.7%)
|
-6.29M
est: -5.92M (-6.1%)
|
-5.90M
-5.90M – -5.90M
+0.4% YoY
|
3.22M
3.22M – 3.22M
+154.5% YoY
|
9.00M
9.00M – 9.00M
+179.9% YoY
|
| SGA |
2.72M
est: 2.55M (+6.5%)
|
3.55M
est: 2.55M (+39.2%)
|
2.94M
est: 51.39M (-94.3%)
|
2.22M
est: 92.12M (-97.6%)
|
1.67M
est: 110.53M (-98.5%)
|
3.70M
est: 2.81M (+31.5%)
|
19.61M
19.61M – 19.61M
+596.9% YoY
|
63.31M
63.31M – 63.31M
+222.9% YoY
|
105.46M
105.46M – 105.46M
+66.6% YoY
|
| EPS |
-0.02
est: -0.01 (-91.6%)
|
-0.03
est: -0.01 (-194.9%)
|
-0.03
est: 0.01 (-362.6%)
|
-0.02
est: 0.03 (-179.4%)
|
-0.01
est: 0.03 (-143.0%)
|
-0.02
est: -0.02 (-5.6%)
|
-0.02
-0.02 – -0.02
+0.4% YoY
|
0.01
0.01 – 0.01
+154.5% YoY
|
0.03
0.03 – 0.03
+179.9% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-08 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Michael Druhan | President of Dermatological Services & Products | 175.5K | male |
| Heinrich De Lange | Chief Technology Officer | — | male |
| John Gevisser | Chief Executive Officer | — | male |
| Meghan Geary | Chief Operating Officer | — | female |
| Scott Naughton | Managing Director of US Operations | — | male |
| Stephen Lockyer | President & Director | — | male |
| Christopher H. Freeman | Corporate Secretary & Acting Chief Financial Officer | — | male |
| Wayne D. Cockburn | Executive Vice President of Laser | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for MDXHF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
